Sanofi and GSK close to reaching $624 Million U.K. Vaccine Deal
Sanofi and GlaxoSmithKline are close to reaching a 500 million-pound ($624 million) deal to supply the United Kingdom government with
Read more
Immunology
Tesla to help COVID-19 vaccine developer CureVac with molecule printers
Tesla Inc is engineering mobile molecule printers to help produce the future COVID-19 vaccine developed by CureVac in Germany, the
Read more
Clover begins trials of COVID-19 vaccine with Dynavax and GSK adjuvants
The Chinese company Clover Biopharmaceuticals revealed the start of a randomized, double-blind, human stage Phase I placebo-controlled clinical study to
Read more
AstraZeneca to supply up to 400 million doses of Oxford’s vaccine free
AstraZeneca has come to an agreement with the European Inclusive Vaccines Alliance (IVA), initiated by Germany, France, Italy and the
Read more
AstraZeneca reaches $750m agreement with CEPI for Oxford COVID-19 vaccine
British pharmaceutical company AstraZeneca has reached a landmark $750 million agreement with Coalition for Epidemic Preparedness Innovation (CEPI) and the
Read more
Vault Pharma designing new Vault-based Coronavirus Vaccine
Vault Pharma is collaborating with UCLA and other universities to develop a coronavirus vaccine with the capacity to treat the
Read more
New Medicine may stop COVID-19 Pandemic ‘Without Vaccination’
A Chinese laboratory has been creating a new antibody medicine considered to have the potential to cease the coronavirus pandemic,
Read more
Qatar Airways Cargo flies 54 tonnes of vaccines from Brussels to Mumbai
Qatar Airways Cargo has transported a 54-tonne shipment consisting of pneumococcal and varicella vaccines from Belgium to India. The 56
Read more
AstraZeneca to advance Oxford’s COVID-19 vaccine with $1bn investment
AstraZeneca is going to expedite the development of the University of Oxford investigational COVID-19 vaccine with a $1 billion BARDA
Read more
CEPI to fund Novavax COVID-19 vaccine with up to $388 Million
CEPI has increased its investment with up to $388 million for the Novavax COVID-19 (NVX‑CoV2373) vaccine development and manufacturing. Phase
Read more